UBS Group
ALGS icon

UBS Group’s Aligos Therapeutics ALGS Stock Holding History

UBS Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Buy
37,061
+36,697
+10,082% +$278K ﹤0.01% 6452
2025
Q4 		$3.39K Sell
364
-15,818
-98% -$149K ﹤0.01% 9034
2025
Q3 		$159K Buy
16,182
+13,439
+490% +$123K ﹤0.01% 6803
2025
Q2 		$19.8K Sell
2,743
-5,718
-68% -$34.2K ﹤0.01% 8452
2025
Q1 		$69.8K Sell
8,461
-7,060
-45% -$155K ﹤0.01% 7330
2024
Q4 		$618K Buy
15,521
+15,507
+110,764% +$300K ﹤0.01% 5694
2024
Q3 		$121 Hold
14
– – ﹤0.01% 9139
2024
Q2 		$127 Sell
14
-419
-97% -$7.37K ﹤0.01% 9128
2024
Q1 		$10.6K Buy
+433
New +$8.62K ﹤0.01% 7217
2023
Q4 		– Sell
-217
Closed -$4.06K – 9255
2023
Q3 		$4.06K Buy
217
+212
+4,240% +$4.7K ﹤0.01% 7481
2023
Q2 		$110 Sell
5
-88
-95% -$2.36K ﹤0.01% 8490
2023
Q1 		$2.04K Buy
+93
New +$3.55K ﹤0.01% 8600
2022
Q1 		– Sell
-302
Closed -$90K – 10188
2021
Q4 		$90K Buy
302
+273
+941% +$99.6K ﹤0.01% 6401
2021
Q3 		$11K Buy
29
+15
+107% +$5.93K ﹤0.01% 7858
2021
Q2 		$7K Sell
14
-131
-90% -$83.5K ﹤0.01% 8307
2021
Q1 		$83K Buy
145
+78
+116% +$51.9K ﹤0.01% 6104
2020
Q4 		$46K Buy
+67
New +$32.6K ﹤0.01% 6256

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

UBS Group's ALGS Position: Q1 2026 in Review

UBS Group increased its Aligos Therapeutics (ALGS) stake by 10,082% in Q1 2026, buying an estimated $278K and bringing the position to 37,061 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #6452.

UBS Group first reported a position in ALGS in Q4 2020 and has held it in 17 quarters since. The position peaked at $618K in Q4 2024. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • UBS Group held 37,061 shares of Aligos Therapeutics worth $275K as of Q1 2026.
  • UBS Group bought 36,697 Aligos Therapeutics shares in Q1 2026, an estimated $278K.
  • Aligos Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6452 holding.
  • UBS Group first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 17 quarters since.
  • UBS Group's Aligos Therapeutics position peaked at $618K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.